The use of myeloid colony-stimulating factors in hematologic malignancies: The role of systematic reviews and meta-analyses

Acta Haematologica

Volumn 125, Issue 1-2, 2010, Pages 68-79

  Gurion, Ronit ^a,b   Shacham Abulafia, Adi ^a,b   Shpilberg, Ofer ^a,b   Raanani, Pia ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

G CSF; GM CSF; Leukemia; Lymphoma; Meta analysis; Systematic review

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; META ANALYSIS (TOPIC); NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

COLONY-STIMULATING FACTORS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; META-ANALYSIS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 78650400916     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318898     Document Type: Review

References (65)

1. Griffin JD: Hematopoietic growth factors; in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2001.
2. Petros PW: Colony stimulating factors; in Chabner BA LD (ed): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, Lippincott Williams & Wilkins, 2001.
3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence- based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
4. Ottmann OG, Bug G, Krauter J: Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol 2007; 44: 183-192.
5. Bennett CL, Stinson TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W, Lazarus HM, Kaminer L, Golub RM, Rowe JM: Economic analysis of a randomized placebocontrolled phase III study of granulocyte macrophage colony stimulating factor in adult patients ( 1 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol 1999; 10: 177-182.
6. Bennett CL, Hynes D, Godwin J, Stinson TJ, Golub RM, Appelbaum FR: Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Invest 2001; 19: 603-610.
7. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J: Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147: 400-411.
8. Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR: Prophylactic granulocyte colony- stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3350-3356.
9. Wittman B, Horan J, Lyman GH: Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev 2006; 32: 289-303.
10. Channa J, Hashmi KZ: Role of recombinant granulocyte-macrophage colony-stimulating factors in reducing the duration of neutropenia. J Coll Physicians Surg Pak 2002; 12: 538-541.
11. Wang J, An L, Chen S, Ouyang J, Zhou R, Chen B, Yang Y: Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis. Acta Haematol 2009; 121: 223-226.
12. Wang J, Zhan P, Ouyang J, Chen B, Zhou R: Prophylactic use of granulocyte colonystimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials. Leuk Lymphoma 2009; 50: 457-459.
13. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE: Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
14. Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK: Randomized placebo- controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146: 54-63.
15. Gurion R, Belnik YP, Gafter AG, Paul M, Vidal L, Ben-Bassat I, Shpilberg O, Raanani P: Myeloid colony-stimulating factors do not increase the risk of mortality or disease activity measures in patients with acute myeloid leukemia: systematic review and metaanalysis. Blood (ASH Annual Meeting Abstracts) 2009; 114: 2045.
16. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore M, Mertelsmann R, Welte K: Recombinant human granulocyte colonystimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-65.
17. Griffin JD, Lowenberg B: Clonogenic cells in acute myeloblastic leukemia. Blood 1986; 68: 1185-1195.
18. Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD: The effects of GMCSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771-1776.
19. Lowenberg B, Salem M, Delwel R: Effects of recombinant multi-CSF, GM-CSF, G-CSF and M-CSF on the proliferation and maturation of human AML in vitro. Blood Cells 1988; 14: 539-549.
20. Park LS, Waldron PE, Friend D, Sassenfeld HM, Price V, Anderson D, Cosman D, Andrews RG, Bernstein ID, Urdal DL: Interleukin- 3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood 1989; 74: 56-65.
21. Inoue C, Murate T, Hotta T, Saito H: Response of leukemic cells to the sequential combination of GM-CSF and G-CSF. Int J Cell Cloning 1990; 8: 54-62.
22. Lemoli RM, Gulati SC, Strife A, Lambek C, Perez A, Clarkson BD: Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination. Leukemia 1991; 5: 386-391.
23. Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, Kell J, Homewood J, Campbell K, McGinley S, Wheatley K, Jackson G: Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135: 450-474.
24. Harousseau JL, Witz B, Lioure B, Hunault- Berger M, Desablens B, Delain M, Guilhot F, Le Prise PY, Abgrall JF, Deconinck E, Guyotat D, Vilque JP, Casassus P, Tournilhac O, Audhuy B, Solary E: Granulocyte colonystimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780-787.
25. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A: A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-4718.
26. Rowe JM, Tallman MS: Intensifying induction therapy in acute myeloid leukemia: Has a new standard of care emerged? Blood 1997; 90: 2121-2126.
27. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK: Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981; 58: 1203-1212.
28. Becker PS: Growth factor priming in therapy of acute myelogenous leukemia. Curr Hematol Rep 2004; 3: 413-418.
29. Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-752.
30. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, Furusawa S, Imai K, Takemoto Y, Miura Y, Teshima H, Hamajima N: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83: 2086-2092.
31. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH: A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485.
32. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, Nicolay U, Gaus W, Heimpel H: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995; 9: 3-9.
33. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrere F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T: Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
34. Sung L, Alibhai SM, Beyene J, Gamis A, Almeida R, Smith S, Aplenc R: Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials. Leukemia 2009; 23: 811-813.
35. Gokbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009; 46: 64-75.
36. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 1556-1564.
37. Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, Kyrle P, Knobl P, Pabinger I, Thalhammer R, Schwarzinger I, Mannhalter C, Jaeger U, Heinz R, Linkesch W, Lechner K: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - a randomized phase-III study. Blood 1997; 90: 590-596.
38. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, Wandt H, Koch P, Kolbe K, Heyll A, Bentz M, Peters S, Diedrich H, Dethling J, Meyer P, Nowrousian MR, Loffler B, Weiss A, Kneba M, Foller A, Graf M, Hecht T: Concomitant granulocyte colony- stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86: 444-450.
39. Thomas X, Boiron JM, Huguet F, Reman O, Sutton L, Turlure P, Garban F, Gardin C, Espinouse D, Boulat O, Lheritier V, Fiere D: Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol J 2004; 5: 384-394.
40. Hallbook H, Bjorkholm M, Hagglund H, Smedmyr B: Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma 2009, pp 1-3.
41. Holowiecki J, Giebel S, Krzemien S, Krawczyk- Kulis M, Jagoda K, Kopera M, Holowiecka B, Grosicki S, Hellmann A, Dmoszynska A, Paluszewska M, Robak T, Konopka L, Maj S, Wojnar J, Wojciechowska M, Skotnicki A, Baran W, Cioch M: G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma 2002; 43: 315-325.
42. Sasse EC, Sasse AD, Brandalise S, Clark OA, Richards S: Colony stimulating factors for prevention of myelosuppressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2005; 3:CD004139.
43. Pui CH: Acute lymphoblastic leukemia; in Pui CH (ed): Childhood Leukemias. New York, Cambridge University Press, 2006, pp 439-472.
44. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, Rivera GK, Kun LE, Evans WE, Pui CH: Granulocyte colonystimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101: 3862-3867.
45. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
46. Bodey GP: Infection in cancer patients. A continuing association. Am J Med 1986; 81: 11-26.
47. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322.
48. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J: The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
49. Goldie JH, Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923-931.
50. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
51. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-1170. (Pubitemid 16043865)
52. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65-74.
53. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002; 112: 406-411.
54. Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158-3167.
55. Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28: 2914-2924.
56. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008; 4:CD003189.
57. Hackshaw A, Sweetenham J, Knight A: Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br J Cancer 2004; 90: 1302-1305.
58. Lyman GH, Dale DC, Wolff DA, Culakova E, Kuderer NM, Poniewierski MS, Crawford J: Standard versus dose-intensified chemotherapy with granulocyte colony-stimulating factor for malignant lymphoma: evaluation of risk for acute myeloid leukemia or myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 2008; 112: 2390.
59. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L: Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207-5215.
60. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D: The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771-775.
61. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet JP, Cordonnier C, Frassoni F: Treatment with granulocyte colonystimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-423.
62. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH: Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
63. Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B: Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003; 3:CD003039.
64. Aviles A, Guzman R, Garcia EL, Talavera A, Diaz-Maqueo JC: Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 1996; 7: 392-397.
65. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, Burniat A, Steels E, Vallot F, Sculier JP: Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181-188. (Pubitemid 36056292)